基质金属蛋白酶7、可溶性Fas及Fas配体血清水平预测去势抵抗性前列腺癌多西他赛耐药与生存
该研究在96例去势抵抗性前列腺癌(CRPC)患者中评估化疗前基质金属蛋白酶7(MMP-7)、可溶性Fas(sFas)及Fas配体(FasL)血清水平及其化疗中变化对多西他赛耐药和生存的预测价值。结果显示化疗前较高MMP-7、sFas和前列腺特异性抗原(PSA)水平与多西他赛耐药及较短癌症特异性生存显著相关,高MMP-7为独立预测因子。
要点
- 化疗前高MMP-7、sFas和PSA水平与多西他赛耐药及较短癌症特异性生存显著相关。
- 高MMP-7是多西他赛耐药和不良癌症特异性生存的独立预测因子。
- MMP-7单独或联合PSA可用于治疗监测。
核心结论
- 化疗前血清MMP-7水平可能有助于筛选可能从多西他赛化疗中获益的CRPC患者。
- MMP-7水平单独或联合PSA水平可用于治疗监测。
研究设计与样本
- 研究纳入96例CRPC患者,其中21例多西他赛耐药患者接受单系列治疗,75例多西他赛敏感患者接受重复系列治疗。
- 采用ELISA法测定血清MMP-7、Fas和FasL水平,除96份治疗前血清样本外,还分析了化疗期间采集的987份血清。
主要发现
- 化疗前较高血清MMP-7、sFas和PSA水平与多西他赛耐药显著相关(P分别为0.007、0.001、<0.001)。
- 化疗前较高血清MMP-7、sFas和PSA水平与较短癌症特异性生存显著相关(P分别为<0.001、0.041、<0.001)。
- 多变量分析中,高MMP-7水平仍为多西他赛耐药的独立预测因子(HR 2.298,95%CI 1.354-3.899;P=0.002)。
- 多变量分析中,高MMP-7水平仍为不良癌症特异性生存的独立预测因子(HR 2.11,95%CI 1.36-3.30;P=0.001)。
- 第二个治疗间歇期MMP-7水平升高幅度较大以及第一和第二个治疗间歇期PSA水平升高幅度较大可预测生存。
临床怎么用
- 化疗前检测血清MMP-7水平可能辅助筛选适合多西他赛化疗的CRPC患者。
- 治疗期间监测MMP-7和PSA水平变化可能有助于评估疗效和预测生存。
局限性
- 需在临床试验中嵌入相关性研究以验证这些生物标志物用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the predictive value of pre-chemotherapy matrix metalloproteinase 7 (MMP-7), soluble Fas (sFas) and Fas ligand (FasL) serum levels, as well as their changes during therapy. PATIENTS AND METHODS: Serum levels of MMP-7, Fas and FasL were determined by ELISA in 96 patients with castration-resistant prostate cancer (CRPC): 21 docetaxel-resistant patients who received one single series and 75 docetaxel-sensitive patients who received repeated series of docetaxel. In addition to the 96 pretreatment serum samples, 987 sera collected during chemotherapy were also analysed. RESULTS: Higher pretreatment serum MMP-7, sFas and prostate-specific antigen (PSA) levels were significantly associated with both docetaxel resistance (P = 0.007, P = 0.001, P < 0.001, respectively) and shorter cancer-specific survival (P < 0.001, P = 0.041, P < 0.001, respectively). High MMP-7 level remained an independent predictor of both docetaxel resistance (hazard ratio [HR] 2.298, 95% confidence interval [CI]: 1.354-3.899; P = 0.002) and poor cancer-specific survival (HR 2.11, 95% CI: 1.36-3.30; P = 0.001) in multivariable analyses. Greater increase in MMP-7 levels in the second treatment holiday and greater increase in PSA levels in the first and second treatment holidays were predictive of survival. CONCLUSIONS: Pretreatment serum MMP-7 levels may help to select patients with CRPC who are likely to benefit from docetaxel chemotherapy. Furthermore, MMP-7 levels alone or in combination with PSA levels could be used for therapy monitoring. Correlative studies embedded in clinical trials are necessary to validate these biomarkers for clinical decision-making.
引用
- Szarvas T, Sevcenco S, Módos O, et al. Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. BJU Int. 2018. PMID: 29802777. doi:10.1111/bju.14415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。